CN111840508A - External preparation for preventing and treating male sexual dysfunction and application thereof - Google Patents
External preparation for preventing and treating male sexual dysfunction and application thereof Download PDFInfo
- Publication number
- CN111840508A CN111840508A CN202010689109.6A CN202010689109A CN111840508A CN 111840508 A CN111840508 A CN 111840508A CN 202010689109 A CN202010689109 A CN 202010689109A CN 111840508 A CN111840508 A CN 111840508A
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- external preparation
- sexual dysfunction
- preventing
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 206010057672 Male sexual dysfunction Diseases 0.000 title claims abstract description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 30
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 30
- 241000237502 Ostreidae Species 0.000 claims abstract description 25
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 25
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 25
- 235000020636 oyster Nutrition 0.000 claims abstract description 25
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 24
- 239000004475 Arginine Substances 0.000 claims abstract description 21
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000006228 supernatant Substances 0.000 claims abstract description 21
- 210000003899 penis Anatomy 0.000 claims abstract description 19
- 229960003080 taurine Drugs 0.000 claims abstract description 15
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 claims abstract description 14
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960000317 yohimbine Drugs 0.000 claims abstract description 14
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims abstract description 11
- 235000019477 peppermint oil Nutrition 0.000 claims abstract description 11
- 239000000047 product Substances 0.000 claims abstract description 11
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000012154 double-distilled water Substances 0.000 claims abstract description 8
- 229960003639 laurocapram Drugs 0.000 claims abstract description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 5
- 229960003121 arginine Drugs 0.000 claims abstract description 4
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 claims abstract 5
- 210000001808 exosome Anatomy 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 10
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 claims description 9
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 claims description 6
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 6
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 6
- 102000013275 Somatomedins Human genes 0.000 claims description 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 229940116977 epidermal growth factor Drugs 0.000 claims description 6
- 102000035160 transmembrane proteins Human genes 0.000 claims description 6
- 108091005703 transmembrane proteins Proteins 0.000 claims description 6
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 4
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 claims description 3
- 102100025222 CD63 antigen Human genes 0.000 claims description 3
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 claims description 3
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 claims description 3
- UZIOUZHBUYLDHW-MSJHMJQNSA-N Ginsenoside Rf Natural products O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@@H](O)C2)[C@@H]([C@@](O)(CC/C=C(\C)/C)C)CC3)C1)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 UZIOUZHBUYLDHW-MSJHMJQNSA-N 0.000 claims description 3
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 claims description 3
- 239000000232 Lipid Bilayer Substances 0.000 claims description 3
- 108700031126 Tetraspanins Proteins 0.000 claims description 3
- 102000043977 Tetraspanins Human genes 0.000 claims description 3
- 230000000975 bioactive effect Effects 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- CNHRRMQBWQJRPN-UHFFFAOYSA-N chikusetsusaponin LM5 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C1O CNHRRMQBWQJRPN-UHFFFAOYSA-N 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 claims description 3
- NODILNFGTFIURN-GZPRDHCNSA-N ginsenoside Rb2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-GZPRDHCNSA-N 0.000 claims description 3
- PFSIGTQOILYIIU-UHFFFAOYSA-N ginsenoside Rb3 Natural products CC(=CCCC(C)(O)C1CCC2(C)C3CCC4C(C)(C)C(CCC4(C)C3CC(OC5OC(COC6OCC(O)C(O)C6O)C(O)C(O)C5O)C12C)OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C PFSIGTQOILYIIU-UHFFFAOYSA-N 0.000 claims description 3
- JDCPEKQWFDWQLI-LUQKBWBOSA-N ginsenoside Rc Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O JDCPEKQWFDWQLI-LUQKBWBOSA-N 0.000 claims description 3
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 claims description 3
- UZIOUZHBUYLDHW-XUBRWZAZSA-N ginsenoside Rf Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZIOUZHBUYLDHW-XUBRWZAZSA-N 0.000 claims description 3
- SPFXZQZPHXUJSR-UHFFFAOYSA-N ginsenoside-Rc Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1OC2OC(CO)C(O)C2O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C SPFXZQZPHXUJSR-UHFFFAOYSA-N 0.000 claims description 3
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 claims description 3
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 210000002826 placenta Anatomy 0.000 claims description 3
- 210000003954 umbilical cord Anatomy 0.000 claims description 3
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 41
- 239000003814 drug Substances 0.000 abstract description 18
- 229940079593 drug Drugs 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 230000008901 benefit Effects 0.000 abstract description 7
- 210000005226 corpus cavernosum Anatomy 0.000 abstract description 7
- 230000008719 thickening Effects 0.000 abstract description 6
- 238000011049 filling Methods 0.000 abstract description 3
- 238000002347 injection Methods 0.000 abstract description 3
- 239000007924 injection Substances 0.000 abstract description 3
- 230000004044 response Effects 0.000 abstract description 3
- 230000000699 topical effect Effects 0.000 abstract 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 16
- 235000009697 arginine Nutrition 0.000 description 16
- 230000002401 inhibitory effect Effects 0.000 description 10
- 230000036299 sexual function Effects 0.000 description 9
- GQDDNDAYOVNZPG-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C[C]2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3N=C21 GQDDNDAYOVNZPG-SCYLSFHTSA-N 0.000 description 9
- 201000001880 Sexual dysfunction Diseases 0.000 description 8
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 231100000872 sexual dysfunction Toxicity 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 5
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- 102400001368 Epidermal growth factor Human genes 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 201000001881 impotence Diseases 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000001568 sexual effect Effects 0.000 description 4
- 229960003604 testosterone Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000006820 DNA synthesis Effects 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 230000006819 RNA synthesis Effects 0.000 description 2
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 230000002710 gonadal effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000003334 potential effect Effects 0.000 description 2
- 206010036596 premature ejaculation Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 1
- 206010040744 Sinus headache Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000703 anti-shock Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 108010071044 cysteine decarboxylase Proteins 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000009986 erectile function Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 210000002332 leydig cell Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000026232 mitotic prophase Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000018052 penile erection Effects 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000002863 seminiferous tubule Anatomy 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000035911 sexual health Effects 0.000 description 1
- 230000035938 sexual maturation Effects 0.000 description 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000008010 sperm capacitation Effects 0.000 description 1
- 230000019100 sperm motility Effects 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- -1 steroid compound Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Developmental Biology & Embryology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A topical preparation for preventing and treating male sexual dysfunction comprises mesenchymal stem cell supernatant, water-soluble laurocapram, arginine, taurine, oleum Menthae Dementholatum, small molecular oyster peptide, ginsenoside extract, yohimbine extract, Gerber gum and double distilled water; in every 200ml finished product: comprises the following components in volume/volume ratio: 15% of mesenchymal stem cell supernatant, 2% of water-soluble laurocapram, 2% of peppermint oil and 6% of jemba; further comprising according to mass/volume ratio: 5% of arginine, 5% of taurine, 2.5% of small molecular oyster peptide, 2% of ginsenoside extract and 2% of yohimbine extract; the balance, double distilled water was quantified to 200 ml. The invention promotes the filling of blood sinuses of the corpus cavernosum penis, has direct effects on erection aiding, time delay, thickening and the like, and has the advantages of quick response, good curative effect and high safety. The invention is an external application smearing formula, and reduces risks caused by oral administration and penis local drug injection.
Description
Technical Field
The invention relates to the technical field of prevention and treatment of male sexual dysfunction, in particular to an external preparation for preventing and treating male sexual dysfunction and application thereof.
Background
The society develops rapidly, the rhythm of life is accelerated, and men are in more and more intense competition, bear great pressure, suffer from diseases and have particularly prominent sexual health problems. Sexual dysfunction not only affects the physical health of male patients, but also affects the psychological health of the male patients, and symptoms such as depression and decreased self-confidence appear, so that the harmonious happiness of the male quality of life, sexual partners and families is seriously affected. Male sexual dysfunction includes: 1. no libido, 2. no erection, 3. premature ejaculation, 4. no ejaculation, and 5. no orgasm. The etiology of the disease is complex and comprises nerve injury, vascular endothelial injury, metabolic abnormality, nutrition, medicines, psychological factors, bad life style and the like.
The male sexual dysfunction needs to be discovered and treated early, so that the male self-confidence is increased, the sexual life satisfaction is improved, other chronic diseases related to the sexual dysfunction are discovered and treated, the overall health of the male is improved, and the construction of healthy China is promoted.
Disclosure of Invention
Objects of the invention
In order to solve the technical problems in the background art, the invention provides an external preparation for preventing and treating male sexual dysfunction, which promotes the blood sinus engorgement of the corpus cavernosum of penis, has direct effects on erection assistance, time delay, thickening and the like, and has the advantages of quick response, good curative effect and high safety.
(II) technical scheme
In order to solve the problems, the invention provides an external preparation for preventing and treating male sexual dysfunction, which comprises mesenchymal stem cell supernatant, water-soluble laurocapram, arginine, taurine, peppermint oil, small molecular oyster peptide, ginsenoside extract, yohimbine extract, lugba gum and double distilled water;
in every 200ml finished product:
comprises the following components in volume/volume ratio: 15% of mesenchymal stem cell supernatant, 2% of water-soluble laurocapram, 2% of peppermint oil and 6% of jemba;
further comprising according to mass/volume ratio: 5% of arginine, 5% of taurine, 2.5% of small molecular oyster peptide, 2% of ginsenoside extract and 2% of yohimbine extract;
the rest, double distilled water is quantified to 200ml
Preferably, the purity of arginine is not less than 99.0%, the purity of taurine is not less than 99.0%, the purity of small molecular oyster peptide is not less than 99.0%, the purity of ginsenoside extract is not less than 80.0%, and the purity of yohimbine extract is not less than 98.0%.
Preferably, the ginsenoside extract comprises the following components:
ginsenoside Rc is 3.27g/100g, ginsenoside Rd is 3.01g/100g, ginsenoside Rf is 8.01g/100g, ginsenoside Rg is 14.3g/100g, ginsenoside Rb1 is 0.3g/100g, ginsenoside Rb2 is 6.45g/100g and ginsenoside Re is 10.3g/100 g.
Preferably, the supernatant of the mesenchymal stem cells is filtered by a 0.22 micron filter through a laboratory sterile operation formula method to obtain a filtrate; wherein the mesenchymal stem cells are from generation P2-P10, are umbilical cord, placenta, bone marrow or adipose derived mesenchymal stem cells, and are cultured by a mixture of 5% ultraGRO-Advanced serum substitute; growing the stem cells to 70-80% density, and collecting cell supernatant; the mesenchymal stem cell supernatant is rich in bioactive exosome with the diameter of 30-150 nm.
Preferably, the exosome is in a circular or elliptic cup-shaped structure, the membrane of the exosome is rich in lipid rafts and transmembrane proteins, and the surface of the exosome is a lipid bilayer and has hydrophobicity; exosomes are rich in VEGF (vascular endothelial growth factor), EGF (epidermal growth factor) and IGF (insulin-like growth factor).
Preferably, the transmembrane proteins are tetraspanin proteins CD63 and CD 81.
Preferably, the final product can be prepared in the form of gel, cream or cream.
An application method of an external preparation for preventing and treating male sexual dysfunction comprises the following steps:
the external preparation for preventing and treating male sexual dysfunction is smeared on the male penis, 5-10 drops of the external preparation are smeared, and the external preparation is massaged for 5-15 minutes; the preparation is administered 2 times daily for two weeks to two months.
The invention promotes the filling of blood sinuses of the corpus cavernosum penis, has direct effects on erection aiding, time delay, thickening and the like, and has the advantages of quick response, good curative effect and high safety.
The invention is an external application smearing formula, and reduces risks caused by oral administration and penis local drug injection.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the description is intended to be exemplary only, and is not intended to limit the scope of the present invention. Moreover, in the following description, descriptions of well-known structures and techniques are omitted so as to not unnecessarily obscure the concepts of the present invention.
The invention provides an external preparation for preventing and treating male sexual dysfunction, which comprises mesenchymal stem cell supernatant, water-soluble laurocapram, arginine, taurine, peppermint oil, small molecular oyster peptide, ginsenoside extract, yohimbine extract, luba gum and double distilled water;
in every 200ml finished product:
comprises the following components in volume/volume ratio: 15% of mesenchymal stem cell supernatant, 2% of water-soluble laurocapram, 2% of peppermint oil and 6% of jemba;
Further comprising according to mass/volume ratio: 5% of arginine, 5% of taurine, 2.5% of small molecular oyster peptide, 2% of ginsenoside extract and 2% of yohimbine extract;
the balance, double distilled water was quantified to 200 ml.
In an alternative embodiment, the purity of arginine is not less than 99.0%, the purity of taurine is not less than 99.0%, the purity of small molecular oyster peptide is not less than 99.0%, the purity of ginsenoside extract is not less than 80.0%, and the purity of yohimbine extract is not less than 98.0%.
Small molecular oyster peptide: belongs to male functional peptide with the purity of 99 percent; the small molecular peptide is easier to be absorbed and utilized by organisms than polypeptide and amino acid, especially dipeptide and tripeptide, the absorption speed of the small peptide in the bodies is higher than that of corresponding free amino acid, the small molecular peptide can be utilized by cavernous cells at a higher speed after entering skin blood through transdermal agent, the local absorption efficiency is improved, and the risk of influencing the first pass effect of the liver and the reduction of the distribution availability of penile tissue of the medicine by oral administration is reduced. The oyster peptide has outstanding antioxidation effect because it contains a large amount of aspartic acid, glutamic acid, cysteine, leucine, lysine and arginine. The oyster peptide is used as a good free radical scavenger and antioxidant, and also has blood pressure lowering effect. A human body acts on HS-Leu at the carboxyl terminal of fifth angiotensin I through Angiotensin Converting Enzyme (ACE) to generate angiotensin II, so that the blood pressure is increased, and bradykinin is inactivated so that the arterial blood pressure is increased, therefore, the inhibiting effect of the ACE activity is a main index for evaluating oyster peptide blood pressure reduction, the inhibiting rate of oyster active peptide on the ACE activity is 36.17% in related documents, and AP-LEU-THR-ASP-TYR which is separated and identified has a strong inhibiting effect on ACE, and the oyster active peptide has a good application foundation for male sexual dysfunction patients suffering from cardiovascular diseases (CVD), lipid oxidation injury and atherosclerosis.
Meanwhile, modern researches show that the oyster peptide has the effects of protecting and repairing islet beta-cells, can promote the repair and recovery of islet cells and the secretion function of the islet cells, and remarkably reduces the blood sugar level in an animal body with a diabetes mellitus model. Meanwhile, the oyster peptide has no influence on the blood sugar of healthy mice, and the normal blood sugar metabolic process is not influenced. The method provides reliable guarantee for the oyster peptide to be used for male patients with the sexual dysfunction of the diabetic basic disease. The oyster peptide can increase the weight of immune organs and the content of serum hemolysin of mice, and obviously increase antibody-producing cells and delayed allergic reaction, which shows that the oyster peptide has good immunity enhancing function and anti-fatigue capability. Meanwhile, the oyster peptide has a certain inhibiting effect on tumor cells, and has low toxicity and high-efficiency anti-tumor effect. In addition, the compound preparation can also improve the learning and memory ability and has good application foundation for male dysfunction patients with nervous system degenerative diseases.
Peppermint oil: pungent and cool in flavor, entering lung and liver meridians; the peppermint oil is light yellow or yellow green liquid, has peculiar fragrance of peppermint, and comprises more than 50 percent of menthol, 20 to 30 percent of menthone and 6 to 10 percent of menthyl ester. The peppermint oil has good auxiliary improvement effect on impotence and premature ejaculation caused by liver depression and qi stagnation. The oleum Menthae Dementholatum has effects of resisting infection, tranquilizing, relieving itching, dispersing stagnated liver qi, relieving qi stagnation, simultaneously has weak local anesthesia and anti-irritant, and has effects of inducing cool feeling, inhibiting pain nerve, and regulating sexual disorder patients with liver qi stagnation.
The luba gum is colorless viscous liquid, is a better skin moisturizer and lubricant, effectively improves the rheological property of the product, has the pH value closer to the acidity of normal skin, and does not cause any stimulation to the skin.
Yohimbine extract is derived from Carcinia Makino bark extract, has purity of 98%, and can be used for improving male sexual function, such as erection promoting, hardness increasing, libido improving, and male sexual impotence and sexual hypofunction improving. The basic principle is to selectively block presynaptic alpha 2 receptors and promote the release of norepinephrine. It can release more noradrenaline from the nerve ending of cavernous body, reduce venous reflux of penis and promote engorgement and erection. When applied in small amount, it can swell perineum, stimulate spinal cord erection center to enhance sexual function, and can be used for treating functional impotence. The traditional yohimbine oral preparation has large side effect, discomfort of intestines and stomach, hypertension, accelerated heartbeat, dizziness, gastrointestinal problems, abnormal excitation, shivering, sleep disorder, anxiety, sinus pain, irritability, headache, frequent micturition, rash, nausea, vomiting and the like, but the traditional yohimbine oral preparation reduces the toxic and side effect by local application and improves the local curative effect of the medicine.
Arginine and nutrients for resisting oxidative stress injury of human body are beneficial to improving immunity of organism, enhancing physical strength and resisting disease. As a precursor substance for Nitric Oxide (NO) synthesis, the arginine is of special significance to men in the aspects of erection, spermatogenesis and capacitation, and energy metabolism in the fertilization process needs arginine. It can promote arginine absorption by local massage, increase NO content in penis endothelial cell to achieve erection promoting effect, and is called as male natural sexual function health product. The penis wants to erect and can be maintained under sufficient NO state, and the most natural method for increasing NO is to use arginine, which can make the endothelial cells of the penis obtain more NO content, thereby promoting the erection. In one study, it was found that a male patient suffering from erectile dysfunction could have a general improvement in sexual function if they took about 5g of arginine per day for 6 weeks. Meanwhile, the cardiovascular and cerebrovascular diseases are the number one killers, the sexual dysfunction of the male is influenced, the probability of the cardiovascular and cerebrovascular diseases occurring in many developed countries is very high, arginine can obviously increase the blood flow in the blood vessel, the systemic circulation is improved, and the cardiovascular and cerebrovascular diseases have certain improvement effect on heart failure or angina pectoris. Meanwhile, diabetes is a common metabolic disorder disease, the sexual function of men can be affected, insulin secretion can be effectively promoted by supplementing a proper amount of arginine, and the tolerance of the body to glucose is improved, so that the sexual function of men is recovered. In addition, hypertension has damage to vascular endothelium due to excessive pressure on the inner wall of blood vessel, which has resulted in vascular sclerosis and sexual dysfunction for a long time, and arginine is effective for improving blood pressure.
Taurine has a wide range of physiological functions and is an important substance for regulating the normal physiological functions of the body. It is also one of the final free amino acids of penis, prostate and testis. Has definite effect on gonadal axis, promotes the secretion of luteinizing hormone, follicle stimulating hormone and testosterone, can stimulate the development of male pituitary, and has no effect on estrogen level. Taurine, a conditionally essential amino acid, can be synthesized by cysteine decarboxylase in the testis group, and its ability to synthesize decreases with age. The effect of taurine on the secretion capacity of leydig cells and testosterone: stimulating testosterone secretion to promote the development of testis of young male mice, and delaying the degeneration of testis structure and function to improve the reproductive function of males, especially elderly males. The taurine can obviously stimulate the synthesis of testosterone in multiple links, improve the activity of sperms, improve the tissue morphology of testis of old men, prevent the degeneration of seminiferous tubules and the degeneration of germ cells and delay the apoptosis atrophy of interstitial cells.
At present, the number of male sexual dysfunction patients is large, although the number of oral yang-tonifying medicines such as Viagra or health-care products is large, the toxic and side effects of the oral medicines are not ignored, and meanwhile, the oral medicines can increase the first-pass effect of the medicines in the liver, reduce the curative effect and greatly reduce the medicine concentration which really achieves the effect of the cavernous body of the penis.
According to the invention, the absorption of the medicine in the corpus cavernosum of the penis is completed through a transdermal technology of local smearing of the penis, so that the maximum utilization of the medicine is achieved.
In the invention, the potential action mechanism of the NO pump and the alpha 2 adrenergic receptor blocker in the cavernous body on the erectile function is combined to act through the transdermal agent, so that the medicine is absorbed, and the effects of erection assistance, thickening and sexual desire increase are achieved.
In the invention, the mesenchymal stem cell supernatant (containing exosome), the micromolecular oyster peptide and the ginsenoside extract promote the absorption of the corpus cavernosum by massage, increase the capillary vascular network hyperplasia of the corpus cavernosum of the penis, promote the increase of the volume of the blood sinuses, and have the effects of thickening, erection assistance and hardness increase.
In an alternative embodiment, the ginsenoside extract comprises the following components: ginsenoside Rc is 3.27g/100g, ginsenoside Rd is 3.01g/100g, ginsenoside Rf is 8.01g/100g, ginsenoside Rg is 14.3g/100g, ginsenoside Rb1 is 0.3g/100g, ginsenoside Rb2 is 6.45g/100g and ginsenoside Re is 10.3g/100 g.
Ginsenoside is a steroid compound, triterpene saponin, and is mainly found in Panax medicinal materials. Ginsenoside is considered as an active ingredient in ginseng and has basic effects including induction of apoptosis of cancer cells, enhancement of immunity of the body, alleviation of toxin action, and anti-fatigue action.
In the invention, the ginseng extract containing 80 percent of ginsenoside is taken as the main material, the ginsenoside can accelerate the sexual maturation process, has good promotion effect on the sexual function recovery and the sexual organ development, and has better improvement effect on the sexual function reduction caused by stress. This effect directly induces penile erection-related vasodilation not by altering hormone release levels but by ginsenoside directly affecting central nervous and gonadal tissues.
In addition, ginsenoside related compounds have different action mechanisms:
rg: exciting central nerve, resisting fatigue, improving memory and learning ability, and promoting DNA and RNA synthesis;
rg 1: rapidly relieving fatigue, improving learning and memory, delaying aging, exciting central nerve, and inhibiting platelet aggregation;
rg 2: anti-shock effect, rapid improvement of myocardial ischemia and anoxia, and treatment and prevention of coronary heart disease;
rg 3: acting on G2 stage of cell reproductive cycle, inhibiting synthesis of mitotic prophase protein and ATP of cancer cell, slowing proliferation and growth of cancer cell, inhibiting cancer cell infiltration, resisting tumor cell metastasis, and promoting tumor cell apoptosis;
rb 1: affecting testicular function, enhancing the choline system, increasing acetylcholine synthesis and release, and improving memory;
Rb 2: promoting DNA and RNA synthesis, inhibiting central nerve, reducing intracellular calcium, resisting oxidation, scavenging oxygen free radicals, and improving myocardial ischemia and reperfusion injury;
rc: belongs to sterol molecules in ginseng, inhibits cancer cells and increases sperm motility;
rd: protecting cardiovascular function, scavenging free radicals, inflammation and radiation injury, improving renal function, resisting aging and lipid peroxidation, improving nervous system and relieving pain, and enhancing memory function and immunoregulation and anti-tumor effects;
re has the functions of resisting arrhythmia, resisting apoptosis and improving cardiac function, and has protective effect on early cardiac damage of diabetic cardiomyopathy;
rh: inhibiting central nerve, hypnotizing, relieving pain, tranquilizing, relieving fever, and promoting synthesis of serum protein;
rh 1: promoting hepatocyte proliferation and DNA synthesis, and treating and preventing hepatitis and liver cirrhosis;
rf: anti-inflammatory, detoxicating, antithrombotic, anxiolytic, intelligence improving, deficiency tonifying, and blood pressure lowering effects;
the ginsenoside is used for male sexual dysfunction, is not as instant as hormone drugs, but has no side effect on human body, can be used for a long time, and achieves the effect of treating both principal and secondary aspects of diseases.
In an alternative embodiment, the mesenchymal stem cell supernatant is prepared by a laboratory sterile operating formulation method, and a filtrate is obtained after filtering the mesenchymal stem cell supernatant by using a 0.22 micron filter;
Wherein the mesenchymal stem cells are P2-P10 generation, the source can be tissues such as umbilical cord, placenta, bone marrow, fat and the like, the mesenchymal stem cells are cultured by a mixture of 5 percent ultraGRO-Advanced serum substitute, the cell density is increased to about 70 to 80 percent, and the supernatant of the stem cells is collected; the mesenchymal stem cell supernatant is rich in exosome with bioactive components of 30-150nm in diameter.
In an alternative embodiment, the exosome is in a circular or elliptic cup-shaped structure, the membrane of the exosome is rich in lipid rafts and transmembrane proteins, and the surface of the exosome is a lipid bilayer and has hydrophobicity; the exosome is rich in biological active substances such as VEGF (vascular endothelial growth factor), EGF (epidermal growth factor) and IGF (insulin-like growth factor), has potential effect on repairing male corpus cavernosum, and can effectively play a biological function through transdermal effect.
In an alternative embodiment, the transmembrane proteins are tetraspanin proteins CD63 and CD 81.
In an alternative embodiment, the finished product can be prepared into a gel, cream or cream shape, so that the product is convenient to apply and use.
In conclusion, the invention provides an external preparation formula combining mesenchymal stem cell supernatant (containing exosome) with small molecular oyster peptide, amino acids, traditional Chinese medicine extract and the like in the aspect of improving male sexual function. Aims to directly accelerate the absorption of the cavernous body of the medicament and promote the filling of the blood sinuses of the cavernous body of the penis by the transdermal action of an NO pump and an alpha 2 adrenergic receptor blocker and the permeation and nourishing principle of a stem cell exosome, and has direct effects on erection assistance, time delay, thickening and the like. On the other hand, the oral health care product has more advantages than the traditional oral health care product which can bring delay or potential side effects. The invention has the advantages of quick effect, good curative effect and good safety.
A method for using an external preparation for preventing and treating sexual dysfunction, comprising the steps of:
coating the external preparation for preventing and treating sexual dysfunction on male penis, smearing 5-10 drops of the external preparation, and massaging for 5-15 minutes; the composition is administered 2 times daily for two weeks to two months, or even longer.
The invention contains biological medicines, is filled by using a vacuum pump, avoids cover opening pollution, and is recommended to be placed in a cool place or a refrigerator at 4 ℃ for refrigeration when not used.
In the invention, although no preservative is added in the formula, the formula is also related to the addition of the peppermint oil, so that the formula has the effects of sterilizing, soothing the liver, relieving depression and refreshing the skin, and can be used without cleaning after being applied.
Example 1: the external preparation for preventing and treating sexual dysfunction is packaged by 30ml and is used for 6 male trials, and the using time is 2 weeks to 2 months. Has no anaphylaxis and toxic side effect. Massaging for 5-15 minutes each time 2 times a day by combining with manipulations to fully promote the absorption of essence.
The use case data is shown in table 1:
TABLE 1
As shown in Table 1, the external preparation for preventing and treating male sexual dysfunction of the present invention has the advantages of wide application age, good use effect and quick curative effect.
The invention is externally applied, and reduces the risk caused by oral administration and penis local drug injection.
It is to be understood that the above-described embodiments of the present invention are merely illustrative of or explaining the principles of the invention and are not to be construed as limiting the invention. Therefore, any modification, equivalent replacement, improvement and the like made without departing from the spirit and scope of the present invention should be included in the protection scope of the present invention. Further, it is intended that the appended claims cover all such variations and modifications as fall within the scope and boundaries of the appended claims or the equivalents of such scope and boundaries.
Claims (8)
1. An external preparation for preventing and treating male sexual dysfunction, which is characterized by comprising mesenchymal stem cell supernatant, water-soluble laurocapram, arginine, taurine, peppermint oil, small molecular oyster peptide, ginsenoside extract, yohimbine extract, luba gum and double distilled water;
in every 200ml finished product:
comprises the following components in volume/volume ratio: 15% of mesenchymal stem cell supernatant, 2% of water-soluble laurocapram, 2% of peppermint oil and 6% of jemba;
further comprising according to mass/volume ratio: 5% of arginine, 5% of taurine, 2.5% of small molecular oyster peptide, 2% of ginsenoside extract and 2% of yohimbine extract;
The balance, double distilled water was quantified to 200 ml.
2. The external preparation for preventing and treating male sexual dysfunction according to claim 1, wherein arginine has a purity of not less than 99.0%, taurine has a purity of not less than 99.0%, small-molecule oyster peptide has a purity of not less than 99.0%, ginsenoside extract has a purity of not less than 80.0%, and yohimbine extract has a purity of not less than 98.0%.
3. The external preparation for preventing and treating male sexual dysfunction according to claim 1, wherein the ginsenoside extract comprises the following components:
ginsenoside Rc is 3.27g/100g, ginsenoside Rd is 3.01g/100g, ginsenoside Rf is 8.01g/100g, ginsenoside Rg is 14.3g/100g, ginsenoside Rb1 is 0.3g/100g, ginsenoside Rb2 is 6.45g/100g and ginsenoside Re is 10.3g/100 g.
4. The external preparation for preventing and treating male sexual dysfunction of claim 1, wherein the supernatant of mesenchymal stem cells is prepared by a laboratory sterile technique by filtering the supernatant of mesenchymal stem cells with a 0.22 μm filter to obtain a filtrate;
wherein the mesenchymal stem cells are from generation P2-P10, are umbilical cord, placenta, bone marrow or adipose derived mesenchymal stem cells, are cultured by a mixture of 5% ultraGRO-Advanced serum substitute, the density of the stem cells is 70-80%, and cell supernatant is collected; the mesenchymal stem cell supernatant is rich in bioactive exosome with the diameter of 30-150 nm.
5. The external preparation according to claim 4, wherein the exosomes have a circular or elliptical cup-like structure, and are rich in lipid rafts and transmembrane proteins on the membrane, and the surface of the exosomes is a lipid bilayer and has hydrophobicity; exosomes are rich in VEGF (vascular endothelial growth factor), EGF (epidermal growth factor) and IGF (insulin-like growth factor).
6. The external preparation for preventing and treating male sexual dysfunction of claim 5, wherein the transmembrane proteins are tetraspanin proteins CD63 and CD 81.
7. The external preparation for preventing and treating male sexual dysfunction according to any one of claims 1 to 6, wherein the final product is in the form of gel, cream or cream.
8. An application method of an external preparation for preventing and treating male sexual dysfunction is characterized by comprising the following steps:
the external preparation for preventing and treating male sexual dysfunction is smeared on the male penis, 5-10 drops of the external preparation are smeared, and the external preparation is massaged for 5-15 minutes; the preparation is administered 2 times daily for 2-8 weeks.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010689109.6A CN111840508A (en) | 2020-07-17 | 2020-07-17 | External preparation for preventing and treating male sexual dysfunction and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010689109.6A CN111840508A (en) | 2020-07-17 | 2020-07-17 | External preparation for preventing and treating male sexual dysfunction and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111840508A true CN111840508A (en) | 2020-10-30 |
Family
ID=72983200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010689109.6A Pending CN111840508A (en) | 2020-07-17 | 2020-07-17 | External preparation for preventing and treating male sexual dysfunction and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111840508A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113171378A (en) * | 2021-04-30 | 2021-07-27 | 奥启(深圳)创投科技有限公司 | Stem cell exosome preparation for preventing and treating male sexual dysfunction |
| CN113230375A (en) * | 2021-05-27 | 2021-08-10 | 东莞市严选生物科技有限公司 | Preparation process of erection-promoting repair paste |
| CN113388578A (en) * | 2021-08-18 | 2021-09-14 | 斯坦姆（天津）细胞工程技术有限公司 | Preparation method of exosome in umbilical cord mesenchymal stem cells |
| CN118615420A (en) * | 2024-05-30 | 2024-09-10 | 青岛海盈生物科技有限公司 | A kind of external small molecule active peptide aphrodisiac composition and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1261798A (en) * | 1997-07-04 | 2000-08-02 | 里尔2000有限公司 | Medicine containing yohimbine and arginine for treating erectile dysfunction |
| WO2002047670A1 (en) * | 2000-12-15 | 2002-06-20 | Pfizer Limited | Treatment of male sexual dysfunction |
| CN109893542A (en) * | 2018-04-04 | 2019-06-18 | 天津欣普赛尔生物医药科技有限公司 | Stem cell excretion body concentrate gel preparation for treating erectile dysfunction and preparation method thereof and medication |
| CN110496214A (en) * | 2019-09-09 | 2019-11-26 | 北京姿美堂生物技术有限公司 | A kind of oyster peptide combinations and preparation method thereof improving male's sexual |
| CN110585328A (en) * | 2019-10-23 | 2019-12-20 | 孙廷柱 | Gel for strengthening yang, tonifying kidney and maintaining male sexual dysfunction and production method thereof |
-
2020
- 2020-07-17 CN CN202010689109.6A patent/CN111840508A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1261798A (en) * | 1997-07-04 | 2000-08-02 | 里尔2000有限公司 | Medicine containing yohimbine and arginine for treating erectile dysfunction |
| WO2002047670A1 (en) * | 2000-12-15 | 2002-06-20 | Pfizer Limited | Treatment of male sexual dysfunction |
| CN109893542A (en) * | 2018-04-04 | 2019-06-18 | 天津欣普赛尔生物医药科技有限公司 | Stem cell excretion body concentrate gel preparation for treating erectile dysfunction and preparation method thereof and medication |
| CN110496214A (en) * | 2019-09-09 | 2019-11-26 | 北京姿美堂生物技术有限公司 | A kind of oyster peptide combinations and preparation method thereof improving male's sexual |
| CN110585328A (en) * | 2019-10-23 | 2019-12-20 | 孙廷柱 | Gel for strengthening yang, tonifying kidney and maintaining male sexual dysfunction and production method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 肖恒军: "阴茎勃起功能障碍的药物治疗进展", 《医学研究生学报》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113171378A (en) * | 2021-04-30 | 2021-07-27 | 奥启(深圳)创投科技有限公司 | Stem cell exosome preparation for preventing and treating male sexual dysfunction |
| CN113230375A (en) * | 2021-05-27 | 2021-08-10 | 东莞市严选生物科技有限公司 | Preparation process of erection-promoting repair paste |
| CN113388578A (en) * | 2021-08-18 | 2021-09-14 | 斯坦姆（天津）细胞工程技术有限公司 | Preparation method of exosome in umbilical cord mesenchymal stem cells |
| CN118615420A (en) * | 2024-05-30 | 2024-09-10 | 青岛海盈生物科技有限公司 | A kind of external small molecule active peptide aphrodisiac composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111840508A (en) | External preparation for preventing and treating male sexual dysfunction and application thereof | |
| WO2008031322A1 (en) | Application of acetylcholine esterase inhibitor medication of leonurus extractive as cholinomimetic | |
| CN103356751B (en) | The extractive composition of sexual function improving, promotion male genitals regrowth | |
| CN105233010A (en) | Wine capable of invigorating kidney and strengthening Yang and making method thereof | |
| CN1970007A (en) | Capsule for improving sexual function for men | |
| CN109316528B (en) | Medicine for treating male erectile dysfunction and preparation method thereof | |
| JP2000007570A (en) | Anti-endocrine disorders | |
| JP7108325B2 (en) | A pharmaceutical composition for prevention or treatment of gynecological diseases containing an ear mushroom extract as an active ingredient | |
| CN100394859C (en) | Health tea | |
| CN101664499B (en) | Xianhuo kidney tonifying mixture | |
| US9839651B1 (en) | Food supplement for restoring male sex drive (libido) | |
| CN113274482B (en) | Use of oxytocin or a derivative thereof for the preparation of a formulation for the treatment or amelioration of milk deficiency and composition | |
| WO2005049053A1 (en) | Composition comprising a magnesium compound and/or a magnesium saltfor improving sexual dysfunction | |
| CN101129632A (en) | Medicament with function of nourishing kidney, warming Yang, preserving essence and benefiting element and method of producing the same | |
| KR100597563B1 (en) | Health functional food containing eluteroside E having bone growth promoting activity | |
| EP3750532A1 (en) | A food supplement for use in restoring male sex drive (libido) | |
| KR100463263B1 (en) | Extract of Acanthopanax senticosus having longitudinal bone growth promotive effects and pharmaceutical composition containing the same | |
| RU2466735C2 (en) | Drug for treating chronic fatigue syndrome, work capacity increase, treatment and prevention of acute respiratory viral infections | |
| KR100597564B1 (en) | Pharmaceutical composition containing eluteroside E having bone growth promoting activity | |
| FR2916637A1 (en) | Composition, useful to prepare functional food/food supplement to prevent e.g. chronic disorder of alcoholism, comprises extract mixture of five plants comprising German Chamomile, Melissa, Horsetail, Milk Thistle, Echinacea, and excipient | |
| KR100692175B1 (en) | Health functional food for improving kidney activity, anti-fatigue, gangjeong, tonic, sexual function | |
| CN113769026A (en) | Food-therapy health-preserving wine | |
| CN103525640A (en) | Energy-keeping yang-tonifying wine | |
| RU2836322C1 (en) | Biologically active food additive for speed and power performance improvement in sports | |
| CN103860761A (en) | Pharmaceutical composition with effects of improving immunity and resisting fatigue as well as preparation method and application of pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201030 |
|
| RJ01 | Rejection of invention patent application after publication |